Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Marqusee, S.T. Haden, R.D. Utiger.
Subclinical thyrotoxicosis.
Endocrinol Metab Clin North Am, 27 (1998), pp. 37-49
[2.]
D.S. Ross.
Subclinical thyrotoxicosis.
Werner & Ingbar's. The thyroid: a fundamental and clinical text 8th ed, pp. 1007-1012
[3.]
G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway.
The Colorado thyroid disease prevalence study.
Arch Intern Med, 160 (2000), pp. 526-534
[4.]
N.D. Charkes.
The many causes of subclinical hyperthyroidism.
Thyroid, 6 (1996), pp. 391-396
[5.]
B. Biondi, E.A. Palmieri, S. Fazio, C. Cosco, M. Nocera, L. Sacca, et al.
Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients.
J Clin Endocrinol Metab, 85 (2000), pp. 4701-4705
[6.]
Subclinical hyperthyroidism: position statement from the American Association of Clinical Endocrinologists [editorial].
Endocrine Practice, 5 (1999), pp. 220-221
[7.]
American College of Physicians.
Clinical guideline, part 1. Screening for thyroid disease.
Ann Intern Med, 129 (1998), pp. 141-143
[8.]
A.D. Toft.
Clinical practice. Subclinical hyperthyroidism.
N Engl J Med, 345 (2001), pp. 512-516
[9.]
S.T. Haden, E. Marqusee, R.D. Utiger.
Subclinical hyperthyroidism.
Endocrinologist, 5 (1996), pp. 322-327
[10.]
M.H. Samuels.
Subclinical thyroid disease in the elderly.
Thyroid, 8 (1998), pp. 803-813
[11.]
W.M. Wiersinga.
Subclinical hypothyroidism and hyperthyroidism. I. Prevalence and clinical relevance.
Neth J Med, 46 (1995), pp. 197-204
[12.]
B. Biondi, E.A. Palmieri, G. Lombardi, S. Fazio.
Effects of subclinical thyroid dysfunction on the heart.
Ann Intern Med, 137 (2002), pp. 904-914
[13.]
C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Balter, P. Bachazach, et al.
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.
N Engl J Med, 331 (1994), pp. 1249-1252
[14.]
J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn.
Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-15 year cohort study.
Lancet, 358 (2001), pp. 861-865
[15.]
A.W. Haider, M.G. Larson, E.J. Benjamin, D. Levy.
Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death.
J Am Coll Cardiol, 32 (1998), pp. 1454-1459
[16.]
P. Greenland, M.L. Daviglus, A.R. Dyer, K. Liu, C.F. Huang, J.J. Goldberger, et al.
Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart As-sociation Detection Project in Industry.
Am J Epidemiol, 149 (1999), pp. 853-862
[17.]
American Association of Clinical Endocrinologists.
Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism.
Endocr Pract, 8 (2002), pp. 457-469
[18.]
F. Osman, M.D. Gammage, M.C. Sheppard, J.A. Franklyn.
Cardiac dysrhytmias and thyroid dysfunction: the hidden menace.
J Clin Endocrinol Metab, 87 (2002), pp. 963-967
[19.]
V. Fuster, L.E. Ryden.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary.
J Am Coll Cardiol, 38 (2001), pp. 1231-1265
[20.]
M. Vanderpump, J. Ahlquist, J. Franklyn, R. Clayton.
Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism.
BMJ, 313 (1996), pp. 539-544
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición
